By Dr Jia (Jenny) Liu

Book Chapters

Liu J; Ward RL, 2010, 'Folate and one-carbon metabolism and its impact on aberrant DNA methylation in cancer', in Herceg Z; Ushijima T (ed.), Advances in Genetics, Elsevier Inc, Burlington, pp. 79 - 122

Journal articles

Childs S; Ma D; Houghton E; Cosman R; Massey J; Chin V; Valencia V; O’Grady A; Jensen SK; McLaughlin A; Goodwin S; Tao H; Withers B; Noakes C; Horne A; Preisz P; Boyd J; Forstner D; Rodrigues A; Sandhu G; Ibrahim K; Martin C; Kwan B; De Luca N; Buscher H; Cunningham P; Joshua AM; Girgis L; Tran B; Desai J; Harrison SJ; Moore J; Liu J, 2026, 'A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases', Npj Precision Oncology, 10, http://dx.doi.org/10.1038/s41698-026-01462-6

Smith B; Wu VS; Pearce A; Liu J; Shepherd HL; Shaw J; Girgis A; Garvey G; Kirsten L; Zakhary I; Ee C; Ewald D; Miller A; Smith A; Virk AK; Gao J; Taylor N, 2026, 'Designing for delivery: a Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway', Supportive Care in Cancer, 34, http://dx.doi.org/10.1007/s00520-026-11275-9

Liu J; Beal J; Coleman N; Lynam J; Subbiah V, 2026, 'Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation', Eclinicalmedicine, 100, http://dx.doi.org/10.1016/j.eclinm.2026.104211

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance', Clinical Cancer Research, 32, pp. 3991 - 4000, http://dx.doi.org/10.1158/1078-0432.CCR-26-0733

Farahnak F; El-Deiry WS; Lussier YA; Kurzrock R; Magidi S; Bresson C; Enger SA; Liu J; Bar J; Warner JL; Meissner T; Rubin E; Rueter J; Gaddipati H; Kulkarni M; Chen Z; Limaye S; Elsey R; Rubenstein BM; Joshua AM; Al-Shamsi HO; Musallam KM; Wunder F; Raynaud J; Berchem G; Gantenbein M; Al Omari A; Dermime S; Abdel-Razeq H; Saintigny P; Cervantes A; Reddel RR; Aref AT; Martin-Liberal J; Lázaro C; Romera DC; Sekacheva M; Berger R; Pramesh CS; Berindan-Neagoe I; Girda E; Piris-Gimenez A; Farhangfar CJ; Salem ME; Dienstmann R; Salazar R; Frankel NZ; Batist Z; Quintana Y; Batist G, 2026, 'Worldwide Innovative Network Consortium: Building a Common Global Cancer Database', JCO Global Oncology, 12, http://dx.doi.org/10.1200/GO-25-00720

Kocx C; Geraghty L; Rolfe Z; McColl H; Holloway C; Bhadri V; Karve S; Liu J; Hunyor I, 2026, 'Multimodality Cardiac Imaging and Multidisciplinary Collaboration in Monitoring Intracardiac Sarcoma Response to Immunotherapy', Jacc Case Reports, 31, http://dx.doi.org/10.1016/j.jaccas.2026.108576

Liu J; Farrow M; Hsing S; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson A; Park JJ; Rodrigues A; Chan W; Wei J; Cohen J; Underhill C; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study', Clinical Cancer Research, 32, pp. a056 - a056, http://dx.doi.org/10.1158/1557-3265.d32026-a056

McNamee N; Aref A; Poulos R; Craft G; Koh J; Xavier D; Singh A; Kansara M; Robinson P; Hains P; Ballinger M; Liu JJ; Thomas D; Reddel R, 2026, 'Abstract B051: Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program', Clinical Cancer Research, 32, pp. b051 - b051, http://dx.doi.org/10.1158/1557-3265.d32026-b051

Liu J; Beal J; Coleman N; Ma BBY; Loong HH; Zhao H; Seymour L; Westphalen CB; Curigliano G; Subbiah V, 2026, 'Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation', Journal of Clinical Oncology, 44, pp. 1933 - 1944, http://dx.doi.org/10.1200/JCO-26-00034

Smith NJ; Gunasegaran B; McLean A; Kohonen-Corish MRJ; Bucca A; Checkley J; Lee JH; Liu J; Kao S; Boyer M; Mander K; Brown B; Wang XS; O’Sullivan JF; Fazekas de St Groth B; McGuire HM, 2026, 'Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer', Frontiers in Immunology, 17, http://dx.doi.org/10.3389/fimmu.2026.1911262

Jones RH; Pinato DJ; Forster MD; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu J; Cosman R; Benafif S; Edmondson SR; Paull JRA; Main NJ; Angeles J; Spicer J, 2026, 'Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours', European Journal of Cancer, 242, http://dx.doi.org/10.1016/j.ejca.2026.116821

Corry J; Brungs D; Liu J; McDowell L; Thornton R; Mar G; Nicholls T; Ooi EH, 2026, 'Multidisciplinary Care of Locally Advanced Mucosal Head and Neck Cancer: An Australian Perspective', Asia Pacific Journal of Clinical Oncology, 22, pp. 351 - 361, http://dx.doi.org/10.1111/ajco.70005

Smith A; Girgis A; Taylor N; Pearce A; Liu J; Shepherd HL; Wu VS; Garvey G; Kirsten L; Zakhary I; Ee C; Ewald D; Miller A; Shaw J, 2026, 'Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence—results of a three-round online delphi consensus process with Australian health professionals and researchers', Journal of Cancer Survivorship, 20, pp. 766 - 780, http://dx.doi.org/10.1007/s11764-024-01685-1

Liu J; LoRusso P, 2026, 'When herds overgraze: the cost of conformity in oncology drug development', BMJ Oncology, 5, http://dx.doi.org/10.1136/bmjonc-2026-001089

Nindra U; Shivasabesan G; Mellor R; Chua W; Karikios D; Richards B; Liu J, 2026, 'Much ado about mentorship: a qualitative analysis of participant feedback from the inaugural Australian National Oncology Mentorship Programme', Internal Medicine Journal, 56, pp. 417 - 424, http://dx.doi.org/10.1111/imj.70328

McNamee NJ; Liu J; Poulos RC; Aref AT; Reddel RR, 2026, 'Predictive Biomarkers of Antibody–Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics', Clinical Cancer Research, 32, pp. 661 - 673, http://dx.doi.org/10.1158/1078-0432.CCR-25-3103

Liu J; Ruan DY; McNamee N; Reddel RR; Wu HX; Meng Q; Xu RH; Subbiah V; Rimm DL; Pistilli B, 2026, 'A modular framework for antibody–drug conjugate biomarkers', Nature Reviews Clinical Oncology, http://dx.doi.org/10.1038/s41571-026-01213-3

Liu J, 2026, 'A synthetic lethal drug for microsatellite instability cancers', Nature Medicine, http://dx.doi.org/10.1038/s41591-026-04693-z

El-Deiry WS; Hernando-Calvo A; Dizon D; Magidi S; Bresson C; Cheng L; Liu J; Hu Z; Hattum C; Meissner T; Grisson R; Liu L; Oberoi A; Frankel NZ; Wunder F; Kurzrock R, 2026, 'WIN-MTB-2024017 – WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers', Oncotarget, 17, pp. 341 - 352, http://dx.doi.org/10.18632/oncotarget.28899

Varkaris A; Italiano A; Sammons S; Falgas EF; Schram AM; Pistilli B; Schott A; Ortega PT; Wisinski K; Wei M; Nanda R; McGuinness JE; Ahnert JR; Ehsani S; Liu JJ; Timm A; Shen J; Kwak EL; Manich CS; Curigliano G, 2026, '90O Dose optimization of zovegalisib, a novel PI3Kα inhibitor, in patients (pts) with PIK3CA-mutant (m) HR+/HER2− advanced breast cancer (BC): Results from the first-in-human (FIH) study to support the recommended phase III dose', ESMO Open, 11, pp. 106232, http://dx.doi.org/10.1016/j.esmoop.2026.106232

Cohen JE; Taylor N; Webster AC; Liu J, 2026, 'Decentralised oncology trials: decentralisation as a tool, not the goal', BMJ Oncology, 5, pp. e001255, http://dx.doi.org/10.1136/bmjonc-2026-001255

Coleman N; Liu J; Beal J; Subbiah V, 2026, 'Next-generation tumor-agnostic targets on the horizon', Trends in Cancer, http://dx.doi.org/10.1016/j.trecan.2026.08.009

Beal J; Coleman N; Liu J; Sicklick JK; Bryan J; Subbiah V, 2026, 'Precision before incision: neoadjuvant tumor-agnostic therapies', Trends in Cancer, http://dx.doi.org/10.1016/j.trecan.2026.09.001

Tyne T; Ivimey E; Duggan L; Liu J, 2025, 'A personal perspective of patient-centred clinical trials', Oncotarget, 16, pp. 808 - 812, http://dx.doi.org/10.18632/oncotarget.28776

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Yau W; Aktas BY; Cosman R; Cohen JE; Edmondson SR; Paull JRA; Jean-Francois BM; Main NJ; Angeles J; Castellarnau A; Cook N, 2025, 'Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors', Journal of Clinical Oncology, 43, pp. 2918 - 2929, http://dx.doi.org/10.1200/JCO-25-00236

Liu J; Yang J; Sun Y; Gong J; Yue J; Pan Y; Sun M; Song R; Xiao X; Tazbirkova A; Ruan J; Liu Z; Liu Z; Li Z; Sheng L; Qin Y; Ying J; Yu X; Zhang J; Mou Y; Lu C; Chen P; Li S; Li J; Qu X; Deng T; Du J; Zhou A; Li E; Yuan X; Liang X; Yu W; Morris M; Luo Y; Zhao X; Guo Y; Zhou H; Shen L, 2025, 'CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial', Nature Medicine, 31, pp. 3028 - 3036, http://dx.doi.org/10.1038/s41591-025-03783-8

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.2591

Wong M; Tebbutt N; Price T; Mendis S; Al-Asady R; Hsu E; Shafren D; Zdanska O; Liu J, 2025, 'Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal,gastroesophageal or ovarian cancer', Cancer Research, 85, pp. ct115 - ct115, http://dx.doi.org/10.1158/1538-7445.am2025-ct115

Chaffer CL; Milioli HH; San Juan BP; Dear RF; Liu JJ, 2025, 'Abstract 4744: State-gating cancer to prevent chemotherapy-resistance', Cancer Research, 85, pp. 4744 - 4744, http://dx.doi.org/10.1158/1538-7445.am2025-4744

Jackson CC; Liu JJ; Liu HY; Williams SG; Anees A; Noor Z; Lucas N; Xavier D; Hains PG; Bucio-Noble D; Aref AT; Porceddu SV; Ladwa R; Whitfield J; Reddel RR; Zhong Q; Panizza BJ; Robinson PJ, 2025, 'A Proteomic Signature for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of Recurrence', Cancer Research Communications, 5, pp. 580 - 593, http://dx.doi.org/10.1158/2767-9764.CRC-23-0460

Liu J; Farrow M; Seymour L; Desai J; Loong HH; Ivy P; Koyoma T; Cook N; Blagden S; Garralda E; Massard C; Tolcher AW; Adashek JJ; Zhang L; Zhao S; Shen L; Kurzrock R; El-Deiry WS; Subbiah V; Joshua AM, 2025, 'Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials', Journal of Clinical Oncology, 43, pp. 735 - 747, http://dx.doi.org/10.1200/JCO-24-01534

Nindra U; Shivasabesan G; Mellor R; Ng W; Chua W; Karikios D; Richards B; Liu J, 2025, 'Final results of the National Oncology Mentorship Program 2023 and its impact on burnout and professional fulfilment', Internal Medicine Journal, 55, pp. 233 - 240, http://dx.doi.org/10.1111/imj.16574

Pham JP; Staeger R; Joshua AM; Liu J; da Silva IP; Dummer R; Goldinger SM, 2025, 'An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115121

Shekar S; Hall A; Pham J; Crumbaker M; Liu J; Talmor B; Sim HW; Joshua AM, 2025, 'Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials', Endocrine Oncology, 5, http://dx.doi.org/10.1530/EO-25-0027

Ladwa R; McLean LS; McGrath M; Liu J, 2025, 'The evolving role of immune checkpoint inhibitors in cutaneous squamous cell carcinoma: Across the disease spectrum', Ejc Skin Cancer, 3, http://dx.doi.org/10.1016/j.ejcskn.2025.100767

El-Deiry WS; Bresson C; Wunder F; Carneiro BA; Dizon DS; Warner JL; Graff SL; Azzoli CG; Wong ET; Cheng L; Mani SA; Safran HP; Williams C; Meissner T; Solomon B; Rubin E; Porgador A; Berchem G; Saintigny P; Onn A; Bar J; Berger R; Gantenbein M; Chen Z; de Pádua Souza C; Reis RMV; Sekacheva M; Cervantes A; Dahut WL; Annunziata CM; Gober K; Musallam KM; Al-Shamsi HO; Abu-Gheida I; Salazar R; Limaye S; Aref AT; Reddel RR; Al Homsi MU; Rouf A; Dermime S; Al Suwaidi J; Vlad C; Buiga R; Al Omari A; Abdel-Razeq H; Oñate-Ocaña LF; Nielsen FC; Graham L; Rueter J; Joshua AM; Girda E; Libutti S; Riedlinger G; Salem ME; Farhangfar CJ; Mesa RA; Faltas BM; Elemento O; Pramesh CS; Sengar M; Aoyama S; Ikeda S; Berindan-Neagoe I; Gaddipati H; Kulkarni M; Auzias E; Gerogianni M; Wolikow N; Istolainen S; Schlafrig P; Frankel NZ; Ferraro AR; Palma J; Gimenez AP; Hernando-Calvo A; Felip E; Tsimberidou AM; Herbst RS; Tabernero J; Schilsky RL; Liu J; Lussier Y; Raynaud J; Batist G; Magidi S; Kurzrock R, 2025, 'Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients', Oncotarget, 16, pp. 140 - 162, http://dx.doi.org/10.18632/oncotarget.28703

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, '991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', Annals of Oncology, 36, pp. s649, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Yu X; Ying J; Enxiao L; Zhou A; Sun Y; Yue J; Ruan J; Zhang J; Shen L; Du J; Tazbirkova A; Liu J; Qin Y; Morris MF; Li Z; Sun M; Pan Y; Zhang J; Guo Y; Zhou H, 2025, 'Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.', Journal of Clinical Oncology, 43, pp. 4017 - 4017, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4017

Sammons SL; Manich CS; Italiano A; Schram AM; Ortega PT; Schott AF; Guerrero A; Aix SP; Nanda R; Wisinski KB; Segar JM; Wei M; Liu J; Spira AI; McGuinness JE; Ahnert JR; X. C; Sirvén MB; Curigliano G; Varkaris A, 2025, 'Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial.', Journal of Clinical Oncology, 43, pp. 1086 - 1086, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.1086

Pham JP; Zdanska O; Selga M; Javier J; O'Grady A; Chin V; Forstner D; Hsu E; Liu J, 2024, 'Onkolytische Viren zur Verstärkung der PD-1-Hemmung bei metastasierendem kutanem Plattenepithelkarzinom', JDDG Journal of the German Society of Dermatology, 22, pp. 1016 - 1019, http://dx.doi.org/10.1111/ddg.15423_g

Dear RF-G; Liu JJ; Cosman R; Walsh N; Selga M; Perez San Juan B; Purcell C; Chaffer CL, 2024, '4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.', Journal of Clinical Oncology, 42, pp. e13112 - e13112, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e13112

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3014

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu J; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3004

Lillie T; Kichenadasse G; Liu JJ; Hernandez Guerrero T; Calvo E; Jakobsson H; Moreno V; Gan HK; Joyce P; Hyland N; Giovannetti M; Palmer T; McAlpine C; Green D; Symeonides SN, 2024, 'EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.', Journal of Clinical Oncology, 42, pp. 2589 - 2589, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2589

Voskoboynik M; Liu J; Song K-H; Park D-G; Ryu M-H; Chon HJ; Kim C, 2024, 'Abstract CT186: A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors', Cancer Research, 84, pp. ct186 - ct186, http://dx.doi.org/10.1158/1538-7445.am2024-ct186

Nindra U; Shivasabesan G; Mellor R; Chua W; Ng W; Karikios D; Richards B; Liu J, 2024, 'Evaluating Systemic Burnout in Medical Oncology Through a National Oncology Mentorship Program', JCO Oncology Practice, 20, pp. 549 - 557, http://dx.doi.org/10.1200/OP.23.00469

Pham JP; Rodrigues A; Goldinger SM; Sim H-W; Liu JJ, 2024, 'Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14978

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. s528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Back to profile page